强肝胶囊治疗慢性乙型肝炎的临床效果

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (635 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the curative efficacy of Qianggan Capsules in the treatment of chronic hepatitis B (CHB) patients with hepatic fibrosis. Methods From July 2017 to July 2019, 100 patients with CHB admitted to Lianjiang People’s Hospital of Guangdong Province were selected as the research subjects. According to the random number table method, they were divided into control group and treatment group, with 50 cases in each group. Control group was treated with Glucurone Tablets and Compound Vitamin B Tablets, and study group was treated with Qianggan Capsules, all treated for six months. Alanine aminotransferase (ALT), total bilirubin (TBil), albumin (ALB), prothrombin time (PT), platelet derived growth factor BB (PDGF-BB), transforming growth factor β1 (TGF-β1), matrix metalloproteinase 1 (MMP-1), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) were compared between two groups. The change of constitution of traditional Chinese medicine in two groups were observed and the occurrence of adverse reactions was recorded. Results After treatment, ALT and TBil levels were lower than those before treatment, PT was shorter than that before treatment, and ALB level was higher than that before treatment (all P < 0.05). After treatment, there were no significant differences in ALT, TBil, ALB and PT between two groups (P ＞ 0.05). After treatment, PDGF-BB, TGF-β1, MMP-1 and TIMP-1 levels in control group were not significantly differences from those before treatment (P > 0.05). PDGF-BB, TGF-β1 and TIMP-1 levels in treatment group were lower than before treatment, and MMP-1 level was higher than that before treatment. After treatment, PDGF-BB, TGF-β1 and TIMP-1 levels in treatment group were lower than those in control group, and MMP-1 level was higher than those in control group (all P < 0.05). After treatment, there was no significant difference in the change of constitution between control group and that before treatment (P ＞ 0.05); there was statistical significance in the change of constitution in treatment group compared with that before treatment (P < 0.05). After treatment, there was statistically significant difference in the change of constitution between two groups (P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05). Conclusion Qianggan Capsules can improve hepatic fibrosis indexes and improved the constitution of traditional Chinese medicine in patients with CHB.

Key words： Qianggan Capsules Chronic hepatitis B Hepatic fibrosis Constitution of traditional Chinese medicine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Hua1 YANG Liuming1 HUANG Ling1 XIN Hongwu2 ZHAO Yanlong1 XU Junkao1 HUANG Chunrong1 FENG Guanggui1

Cite this article:

WANG Hua1 YANG Liuming1 HUANG Ling1 XIN Hongwu2 ZHAO Yanlong1 XU Junkao1 HUANG Chunrong1 FENG Guanggui1. Clinical effect of Qianggan Capsules in the treatment of patients with chronic hepatitis B[J]. 中国医药导报, 2021, 18(10): 80-83.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I10/80

[1] Shih C，Yang CC，Choijilsuren G，et al. Hepatitis B Virus [J]. Trends Microbiol，2018，26（4）：386-387.
[2] Fanning GC，Zoulim F，Hou J，et al. Therapeutic strategies for hepatitis B virus infection：towards a cure [J]. Nat Rev Drug Discov，2019，18（11）：827-844.
[3] Brancaccio G，Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection [J]. Int J Antimicrob Agents，2019，54（6）：697-701.
[4] 王华，赵延龙，徐克成，等.强肝胶囊联合拉米夫定治疗慢性乙型肝炎肝纤维化的临床病理观察[J].中国中西医结合杂志，2006，26（11）：978-980.
[5] 王华，杨柳明，黄玲，等.强肝胶囊对慢性乙型肝炎患者肝组织病理及PDGF-BB、TGF-β1、TIMP-1、MMP-1的影响[J].中国中西医结合杂志，2011，31（10）：1337-1340.
[6] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）[J].中华流行病学杂志，2011，32（4）：405-415.
[7] 王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报，2005，28（4）：1-8.
[8] 中华中医药学会.《中医体质分类与判定》[M].北京：中国中医药出版社，2009.
[9] 国家中医药管理局.国家中医药管理局关于印发中医药健康管理服务技术规范的通知[Z].2013-09-22.
[10] Ezhilarasan D，Sokal E，Najimi M. Hepatic fibrosis：It is time to go with hepatic stellate cell-specific therapeutic targets [J]. Hepatobiliary Pancreat Dis Int，2018，17（3）：192-197.
[11] Schuppan D，Ashfaq-Khan M，Yang AT，et al. Liver fibrosis：Direct antifibrotic agents and targeted therapies [J]. Matrix Biol，2018，68/69：435-451.
[12] Bissell D. Inflammation and hepatic fibrosis [J]. Semin Liver Dis，2010，30（3）：211-214.
[13] Koyama Y，Brenner DA. Liver inflammation and fibrosis [J]. J Clin Invest，2017，127（1）：55-64.
[14] 柳琳琳，毛德文，吕建林，等.强肝胶囊对非酒精性脂肪性肝病患者疗效及安全性的Meta分析[J].中成药，2018， 40（8）：1715-1720.
[15] 田春阁，常小娴.强肝胶囊联合抗病毒治疗CHB的疗效及对肝纤维化程度、HBV-DNA载量和血清ECM、TGF-β1水平的影响[J].现代诊断与治疗，2019，30（2）：219-220.
[16] Kuo JJ，Wang CY，Lee TF，et al. Paeoniae radix reduces PDGF-stimulated hepatic stellate cell migration [J]. Planta Med，2012，78（4）：341-348.
[17] Ren H，Li Y，Chen Y，et al. Endostatin attenuates PDGF-BB- or TGF-β1-induced HSCs activation via suppressing RhoA/ROCK1 signal pathways [J]. Drug Des Devel Ther，2019，13：499-500.
[18] Ghafoory S，Varshney R，Robison T，et al. Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury [J]. Blood Adv，2018，2（5）：470-480.
[19] Tian F，Liu Y，Gao J，et al. Study on the association between TGF-β1 and liver fibrosis in patients with hepatic cystic echinococcosis [J]. Exp Ther Med，2020，19（2）：1275-1280.
[20] Yilmaz Y，Eren F. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease：association with liver histology [J]. Eur J Gastroenterol Hepatol，2019，31（1）：43-46.
[21] Roderfeld M. Matrix metalloproteinase functions in hepatic injury and fibrosis [J]. Matrix Biol，2018，68/69：452-462.
[22] 余金花，施卫兵，张平，等.106例慢性乙型肝炎患者的中医体质类型分布[J].中医药临床杂志，2017，29（1）：68-71.
[23] 何发娟.慢性乙型肝炎重症化倾向期中医体质类型及蛋白质组学的调查研究[D].南宁：广西中医药大学，2018.
[24] 徐强，刘凤，范灵芝，等.不同免疫状态慢性乙型肝炎患者中医体质类型分布[J].中医杂志，2017，58（14）：1205-1208.